NCT03281291View on ClinicalTrials.gov

Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.

CompletedOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

April 22, 2022

Study Completion Date

October 23, 2023

Conditions
Malaria
Trial Locations (2)

40100

GSK Investigational Site, Kisumu

Unknown

GSK Investigational Site, Kumasi

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03281291 - Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study. | Biotech Hunter | Biotech Hunter